Atox ‘Remains On Track’ Despite ACCUTE Setback

CEO Says Reltecimod NDA In NTSI Set For September

 
• By Sten Stovall
Wooden_Sign
Atox hopes to get FDA approval for reltecimod in NTSI by May 2021 • Source: Shutterstock

More from Clinical Trials

More from R&D